66 results
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
process may act to rapidly prevent complement-mediated nerve damage and irreversible neurological disability. In a prior placebo-controlled proof … primary endpoint, with a single infusion of ANX005 30 mg/kg achieving a highly statistically significant 2.4-fold improvement on the GBS-disability scale (p
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
and irreversible neurological disability. In a prior placebo-controlled proof-of-concept trial, a single dose of ANX005 showed rapid and consistent improvement … statistically significant 2.4-fold improvement on the GBS-disability scale (p = 0.0058). ANX005 30 mg/kg treatment also demonstrated improvements versus placebo
8-K
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
met its primary endpoint, with a single infusion of ANX005 30 mg/kg achieving a statistically significant 2.4-fold improvement on the GBS-disability
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8 (proportional odds analysis, p = 0.0058).
ANX005 30 mg … , and may lead to significant morbidity, disability and mortality. Currently, there are no approved treatments for GBS in the U.S. The long-term
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
results ✓ Less overall disability ✓ No new safety signals ✓ Able to run earlier vs placebo from multiple pre‐ specified ✓ No increased infection rate … Topline Results Subject to Change
GBS: Neurological Emergency with Long-Term Disability; Requires an Immediately Targeted and Effective Intervention
424B5
fxa1todhm v3w
5 Apr 24
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
o8b0w8a
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
6d73pwn
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
q3ts3 z1tluu2r0d6
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm